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CRISPR artificial splicing factors
Menghan Du1,2,6, Nathaniel Jillette1,6, Jacqueline Jufen Zhu1, Sheng Li 1,2,3,4 & Albert Wu Cheng 1,2,3,5✉
Alternative splicing allows expression of mRNA isoforms from a single gene, expanding the
diversity of the proteome. Its prevalence in normal biological and disease processes warrant
precise tools for modulation. Here we report the engineering of CRISPR Artificial Splicing
Factors (CASFx) based on RNA-targeting CRISPR-Cas systems. We show that simultaneous
exon inclusion and exclusion can be induced at distinct targets by differential positioning of
CASFx. We also create inducible CASFx (iCASFx) using the FKBP-FRB chemical-inducible
dimerization domain, allowing small molecule control of alternative splicing. Finally, we
demonstrate the activation of SMN2 exon 7 splicing in spinal muscular atrophy (SMA)
patient fibroblasts, suggesting a potential application of the CASFx system.
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Splicing is a process in which segments of a pre-mRNAcalled introns are removed while segments called exons arejoined together to form mature mRNA1. Alternative spli-
cing is a phenomenon in which different exon segments of a gene
are spliced together to form mature mRNA with varying
sequences, greatly expanding the protein repertoire coded by a
single gene. The process of alternative splicing is deeply embed-
ded in gene regulatory networks and serves to control gene iso-
form expression of >90% of human genes2. Given its prevalence,
it is not surprising that dysregulation of RNA splicing has been
implicated in many diseases3–5. RNA-seq is a powerful tool that
can be used to “read” transcriptomes and identify changes in
alternative splicing within different cell types, conditions and
diseases2,5,6. However, a scalable tool for precisely and reversibly
“writing” alternative splicing is lacking.
Although isoform-specific RNAi targeting a specific gene iso-
form for degradation or isoform-specific cDNA over-expression
can be used to perturb isoform levels7,8, the overall expression
level of the target gene might not be preserved. While splice-
switching antisense oligonucleotides (ASOs) are efficient in per-
turbing splicing and have even advanced into clinical trials9, their
cost is prohibitory for large scale studies and many designs need
to be screened to identify effective target sequences. Also, because
ASOs are transient in nature they are not suitable for use cases
that require either stable or inducible expression.
Fusion of RNA regulatory proteins to heterologous RNA
binding domains, such as Pumilio/PUF, MS2 coat protein (MCP),
PP7 coat protein (PCP), and λN, have allowed artificial mod-
ulation of RNA processes10–15. For example, tethering of serine-
rich or glycine-rich domains by engineered PUF domains to
exons induce their inclusion or exclusion, respectively12. How-
ever, these artificial RNA effectors require either protein engi-
neering or insertion of artificial tags to target RNA and depend on
short recognition sequences which limits targeting flexibility and
specificity.
The fields of genetics and epigenetics have greatly benefited
from an explosion of technologies based on RNA-guided DNA-
targeting CRISPR-Cas systems16. We, among others, have suc-
cessfully implemented molecular tools for modifying genetic
sequences or epigenetic states of target DNA loci17–25. CRISPR-
mediated DNA-level genetic editing approaches have been used
to perturb splicing (base editing/indel at splice sites or cutting out
whole exon)19–21. However, these may have confounding effects
due to potential perturbation of DNA cis-regulatory elements
(e.g., transcription factor binding sites) sharing the same piece of
DNA. In addition, it is difficult to promote exon inclusion with
CRISPR-mediated DNA deletion or mutation methods.
The exciting prospect of using CRISPR to target RNA was first
demonstrated by conversion of the most frequently used DNA-
targeting SpCas9 to an RNA nuclease “RCas9” with the addition
of a PAMmer—an oligo that when bound to target RNA mimics
the Protospacer Adjacent Motif (PAM) required for SpCas9
binding19. Although targeting of RCas9 to repetitive sequences
does not require PAMmer26, repeat sequences constitute only a
small proportion of all RNA cis-regulatory elements. Following
the initial report of RCas9, other CRISPR/Cas9 systems were
also found to bind to single-stranded RNA in vitro27,28, but
evidence for their in vivo RNA binding in mammalian cells is
lacking. RNA-guided RNA nucleases from bacterial CRISPR
systems have recently been discovered29–31. Their adaptation to
mammalian cells has not only allowed programmable RNA
degradation29,31,32 but has also been amenable for engineering
new functions, e.g., RNA sequence editing30, live-cell RNA ima-
ging32, and diagnostics33.
In particular, CasRx is the most recently identified type IV-D
CRISPR-Cas ribonuclease isolated from Ruminococcus flavefaciens
XPD3002 with robust activity in degrading target RNAs matching
designed guide RNA (gRNA) sequences31. Furthermore, dCasRx
with mutated nuclease domains (R239A/H244A/R858A/H863A)
can be programmed to bind splicing elements to inhibit exon
splicing, potentially by blocking access of splicing machinery.
Induction of exon inclusion, however, has yet to be demonstrated.
In contrast to exon exclusion that can be sufficiently induced by
binding of dCasRx alone31, induction of exon inclusion might
require additional splicing factor activity.
In the present work, we create CRISPR Artificial Splicing
Factors (CASFx) by fusing RNA-target Cas proteins with splicing
regulatory domains. We show that exon inclusion and exclusion
can be induced on two targets simultaneously by positioning
CASFx gRNAs on different sequence elements. We further
implement a rapamycin-inducible CASFx using the FKBP-FRB
dimerization domain to allow small-molecule control of splicing.
Finally, we demonstrate activation of SMN2-E7 by CASFx in
spinal muscular atrophy (SMA) fibroblast cells.
Results
CASFx modulates alternative splicing. We fused dCasRx with
splicing factors successfully applied in aptamer tethering assays to
activate exon inclusion when bound downstream of the target
exon in splicing minigenes10,14. Exon 7 of survival motor neuron
2 gene (SMN2-E7) was chosen as our test exon as it has impli-
cations in SMA treatment, and its regulation is well-
characterized34. We first constructed CASFx-1 (RBFOX1N-
dCasRx-C) by replacing the entire RNA recognition motif (RRM)
of splicing factor RBFOX1 (residues 118-189) with dCasRx and
tested its ability to induce inclusion of SMN2-E7 in an SMN2
splicing minigene (Fig. 1a). When HEK293T cells were trans-
fected with pCI-SMN2 (containing the splicing minigene) and
control GFP plasmid (pmaxGFP), the SMN2 minigene expressed
predominantly exclusion isoform (Fig. 1b, lane 1). To activate
SMN2-E7 inclusion, four guide RNAs (gRNAs gSMN2-1 through
4) were designed in the intron downstream of SMN2-E7 and
transfected individually with CASFx-1 and pCI-SMN2 into
HEK293T. These resulted in increased SMN2-E7 inclusion
(Fig. 1b, lanes 11~14, see upper bands). Simultaneous introduc-
tion of two, three, or four intronic gRNAs further increased levels
of E7-included transcripts and decreased the levels of E7-
excluded transcripts, switching the splicing pattern to pre-
dominantly inclusion (Fig. 1b, lanes 15~17). SMN2-E7 activation
is dependent on RBFOX1 effector because dCasRx alone did not
result in activation (Fig. 1b, lanes 3~9). Activation is also
dependent on the binding of CASFx-1 onto the SMN2 intron as
control gRNAs (“C”) did not induce SMN2-E7 inclusion (Fig. 1b,
lane 10). To test whether dCasRx can tether other splicing factors,
we generated two additional CASFx by fusing RBM38 to N- or C-
termini of dCasRx, which we called CASFx-2 (RBM38-dCasRx)
and CASFx-3 (dCasRx-RBM38), respectively. In addition, since
dCasRx binding within exons was shown to induce exon exclu-
sion in a previous study31, we asked whether CASFx could also be
used to induce exon skipping when directed to bind within exons.
Therefore, we designed an exonic (“EX”) gRNA in the middle of
SMN2-E7 (Fig. 2a). When co-transfected with one of the CASFx
and the pool of intronic downstream SMN2-DN (gSMN2-1,2 and
3), SMN2 minigene showed a switch to predominantly inclusion
isoform (Fig. 2b, lanes 6,9,12). Exon inclusion was dependent on
both intronic targeting as well as splicing effector activities, while
SMN2-E7 exclusion could be induced by exonic targeting of
unfused dCasRx or effector-fused CASFx (Fig. 2b, compare lanes
3,5,9,12 and lanes 4,7,10,13), consistent with previous observa-
tions31. These demonstrate that exon inclusion or exclusion can
be induced by the same CASFx by designing gRNA binding to
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different locations on target transcripts. We also quantified spli-
cing changes by quantitative RT-PCR (Fig. 2b, upper column
plot). CASFx-1 induced a 21-fold increase while CASFx-2 and
CASFx-3 induced ~6-fold increases in inclusion/exclusion relative
ratios.
Examining functional splicing activation domains of CASFx-1.
We next asked which part of RBFOX1 N- and C-terminal
domains are required for exon activation by CASFx-1
(RBFOX1N-dCasRx-C). A previous study demonstrated that
RBFOX1 truncation mutants lacking the entire RRM domain are
functional in inducing cassette exon inclusion10. Further trun-
cation experiments demonstrated that the C-terminal domain of
RBFOX1 is sufficient for cassette exon activation when targeted to
the downstream intron10. To identify RBFOX1 domains required
in the context of CASFx-1-mediated exon activation, we gener-
ated a series of RBFOX1 domain truncation mutants (Supple-
mentary Fig. 1a). While full-length CASFx-1 (RBFOX1N-
dCasRx-C) was the most active in promoting exon 7 inclusion
(Supplementary Fig. 1b, lane 2), dCasRx-RBFOX1C fusion (C)
was also able to induce exon 7 inclusion, albeit to a lesser extent
(Supplementary Fig. 1b, lane 4). RBFOX1N-dCasRx fusion (N)
was unable to induce splicing changes (Supplementary Fig. 1b,
lane 3), consistent with a previous report10. Further truncations
of the RBFOX1C domain greatly diminished or abolished splicing
activity (Supplementary Fig. 1b, lane 5–8), suggesting that the full
C-terminal domain is required for CASFx-1-mediated exon
activation, and that the inclusion of N-terminal domain enhances
splicing activation. It is worth noting that the domain require-
ment presented here for CASFx-1-mediated splicing activation
may be different from that for the endogenous RBFOX1 and
should thus be interpreted only in the context of the particular
fusion construct.
Multiplexed splicing modulation by CASFx. Next, we tested
whether more than one splicing event can be modulated simul-
taneously and differentially with CASFx (Fig. 3a). We targeted
CASFx-1 to the splice acceptor site of an RG6 minigene (RG6-
SA) and the intron downstream of SMN2-E7 minigene and
observed simultaneous repression of the RG6 cassette exon (RG6-
CX) and activation of SMN2-E7 (Fig. 3b, lane 4). Since CasRx is
capable of processing gRNAs encoded in tandem in a poly-
cistronic pre-gRNA array by cleaving 5′ of each direct repeat
(DR)31, we asked whether the three SMN2-DN spacers and the
RG6-SA spacer could be transcribed as one polycistronic pre-
gRNA to achieve simultaneous modulation of the two splicing
events. First, we tested if the addition of a preprocessed DR to the
3′ end of gRNA is tolerated by CASFx (Fig. 3a, DR-SMN2-2-DR
and DR-RG6-SA-DR). As predicted, these gRNAs remained
active in inducing SMN2-E7 inclusion and RG6-CX exclusion
(Fig. 3b, lanes 5,6). More importantly, a polycistronic pre-gRNA
(SMN2-DN-RG6-SA) harboring the three SMN2-DN spacers and
the RG6-SA spacer induced simultaneous SMN2-E7 inclusion
and RG6-CX exclusion when transfected with CASFx (Fig. 3b,
lane 7), confirming the functionality of the polycistronic pre-
gRNA architecture in inducing simultaneous and bidirectional
splicing modulation of two different targets.
Comparison of CASFx with PUF-based engineered splicing
factor. Previously, engineered splicing factors (ESFs), based on
the fusion of splicing factors with programmable RNA-binding
PUF domains (PUF-ESFs), have been reported to modulate
alternative splicing12. Here we compared the efficiency and spe-
cificity of CASFx with PUF-based ESF (PUF-ESF). To do this we
assembled three PUF-ESF modules designed to bind to the same
locations as the three CASFx-SMN2-gRNA target sequences
(Fig. 4a). Transfection with one of the three PUF-ESFs induced
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Fig. 1 Exon inclusion induced by CASFx-1 (RBFOX1N-dCasRx-C). a Schematic of the CASFx-1 and SMN2 minigene. The RNA binding domain of RBFOX1
was substituted by dCasRx to create an RNA-guided CRISPR Artificial Splicing Factor 1 (CASFx-1) RBFOX1N-dCasRx-C. The SMN2 minigene on plasmid
pCI-SMN2 contains exons 6 (E6) and 8 (E8) that are constitutively spliced, and exon 7 (E7) that is alternatively spliced, and the intervening introns, driven
by the CMV promoter (pCMV). Four designed guide RNA (gRNA) target sites are indicated by numbered boxes 1 through 4 within the intron between E7
and E8. pCI-F and pCI-R indicate primers used for semi-quantitative RT-PCR assays. b Gel image of splicing RT-PCR using primers pCI-F and pCI-R on
SMN2 minigene transcripts in cells co-transfected with control GFP plasmid (pmaxGFP), unfused dCasRx, or CASFx-1 (RBFOX1N-dCasRx-C), and the
indicated gRNAs, numbers correspond to those in panel a with dash indicating the range of gRNAs used. “C” indicates a control gRNA not matching SMN2
minigene. Upper and lower bands correspond to the E7-included and -excluded transcripts, respectively. Reference splicing bands derived from E7-
excluded sample (pCI-SMN2-MS2) and E7-included sample (pCI-SMN2-MS2+MCP-RBFOX)10 serve as molecular weight markers (M) for inclusion (Inc)
and exclusion (Exc) events. The image shown is representative of two independent experiments. Uncropped gel images are included in the Source Data file.
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SMN2-E7 inclusion (Fig. 4b, lanes 2~4). The co-transfection of
the three PUF-ESFs did not provide an additive effect on exon 7
inclusion compared with PUF-ESF3-only transfection (Fig. 4b,
lane 5). As we show above, cells transfected with separate CASFx
effectors and gRNA plasmids also showed an increase of the
inclusion isoform and a decrease of the exclusion isoform
(Fig. 4b, lanes 14, 17 and 20). We also constructed two all-in-one
CASFx constructs expressing both CASFx effectors and three
gRNAs (Fig. 4a). CASFx all-in-one plasmids provided the most
efficient splicing induction (Fig. 4b, lane 7 and 9). Quantification
by RT-PCR revealed a 14-fold increase in the inc/exc relative ratio
with the CASFx-1 all-in-one sample and more than a 7-fold
increase with the CASFx-3 all-in-one sample. Of the three PUF-
ESF tested, PUF-ESF3 had the strongest induction with an
approximately 10-fold increase (Fig. 4b lane 2~4). These data
demonstrate that splicing activation offered by CASFx is on-par
with PUF-ESF.
Off-target effects are a major concern for any sequence-based
gene editing methods. We therefore investigated the genome-
wide specificity of CASFx and PUF-ESF using RNA-seq. Four
off-target splicing changes were induced by CASFx-1 and two
were induced by CASFx-3 (Fig. 4c i and ii). For cells transfected
with PUF-ESFs, analysis of alternative splicing changes revealed
59 off-target splicing changes (Fig. 4c iii). These results
demonstrate that CASFx-1 and CASFx-3 offer higher specificity
compared with PUF-ESF. One caveat for such interpretation,
however, is that the higher off-target effects of PUF-ESF could
also result from the relatively higher molar amount of the three
PUF-ESFs transfected as separate plasmids. No significant
changes in endogenous SMN2 splicing were detected by RNA-
seq (Fig. 4c). It is because the high sequence homology between
SMN1 and SMN2 and the constitutive inclusion of SMN1 exon 7
in HEK293T preclude accurate quantification of endogenous
SMN2-E7 splicing level.
For CASFx, off-target effects may result from mismatch
tolerance between the gRNA and the target RNA. To investigate
the contribution of mismatch tolerance to the observed CASFx
off-targets, we generated sequence match profiles of the three
gRNA spacers against sequences encompassing the upstream
intron, cassette exon, and downstream intron of the off-target
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Fig. 2 Activation and repression of exon by differential positioning of CASFx. a Schematic of the CRISPR artificial splicing factors, CASFx-1 (RBFOX1N-
dCasRx-C), CASFx-2 (RBM38-dCasRx), CASFx-3 (dCasRx-RBM38) and SMN2 minigene, as well as a set of three target sites downstream of E7 (DN:
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represented as mean ± SD (n= 3). Lower panel shows a gel image of semi-quantitative splicing RT-PCR of the corresponding samples. “C” indicates a
control gRNA without matching SMN2 minigene sequence; “DN” indicates a pool of three gRNAs (SMN2-gRNA-1 through 3) targeting downstream of E7;
“EX” indicates a gRNA targeting within E7. Uncropped gel images and qRT-PCR values are included in the Source Data file.
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minigene plasmids, CASFx-1 and the indicated gRNAs. Uncropped gel images and qRT-PCR values are included in the Source Data file.
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events (Supplementary Figs. 2 and 3, Supplementary Table 3). Of
the observed off-targets, the closest matches (16 nt) between
gRNA and off-target RNA are located on the intronic regions of
DNAAF5 and CTDSPL (Supplementary Figs. 2 and 3). To avoid
the potential off-target effects in future studies, gRNA designs
should consider imperfect transcriptomic matches.
Since RBFOX1 and RBM38 are tissue-specific splicing factors,
we asked whether their splicing effector activity could be
extended to other cell types when tethered by dCasRx. We tested
CASFx-1 and CASFx-3 for activating SMN2-E7 in HeLa and
U2OS cell lines. As expected, targeting of these CASFx at intronic
or exonic regions resulted in the inclusion and exclusion of
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SMN2-E7 on SMN2minigene respectively (Supplementary Fig. 4).
Utilizing similar design principles, we used CASFx-1 and CASFx-
3 to rescue a minigene cassette exon splicing of a bona fide
RBFOX target, NUMA1, in an RBFOX2-knockdown HeLa and
U2OS cells (Supplementary Fig. 5). These results show that
CASFx composed of tissue-specific splicing factors can be applied
in different cell types, and can be used for studying the functions
of splicing factors and individual target exons.
Inducible CASFx platform. To enable tunable control for
CASFx, we created two-peptide inducible CRISPR Artificial
Splicing Factors (iCASFx) using rapamycin-inducible FKBP-FRB
chemically inducible domains (CID)35. We separated the RNA
binding module (FKBP-dCasRx, or dCasRx-FKBP) and exon
splicing effector module (RBFOX1N-FRB-C), into two peptides
that can be induced to interact via the FKBP-FRB domains in the
presence of rapamycin (Fig. 5a). Induction of SMN2-E7 inclusion
was observed in cells cultured with rapamycin and transfected
with iCASFx plus SMN2-DN-gRNA plasmids (Fig. 5b, lanes 3
and 8), inducing more than a 4-fold increase in inc/exc relative
ratio by FKBP-dCasRx and 3.8-fold increase by dCasRx-FKBP.
SMN2-E7 was not induced when RBFOX1N-FRB-C module was
replaced by FRB-Clover (Fig. 5b, lane 6 and 11), demonstrating
that rapamycin, dCasRx target binding, and RFBOX1/RBM38
effector domains are all required for the inducible splicing
modulation. When cells were co-transfected with iCASFx and
control gRNA or RG6-SA, a slight increase of the inclusion iso-
form was observed (Fig. 5b, lanes 4, 5, 9 and 10). This non-
specific increase might have resulted from the non-specific
binding of the iCASFx that was not observed in the constitutive
CASFx constructs, pointing to the need for additional optimiza-
tion of the inducible system.
CASFx-mediated modulation of endogenous SMN2 splicing.
Having demonstrated the success of CASFx in regulating alter-
native splicing on minigenes, we next investigated whether
CASFx could be applied to endogenous transcripts. In addition to
dCasRx-based CASFx, we were interested to see if CASFx could
also be constructed using catalytically inactive dPspCas13b,
derived from a Cas13b effector from Prevotella sp. P5-12530. To
this end, we swapped dPspCas13b into CASFx-1 in place of
dCasRx, generating RBFOX1N-dPspCas13b-C (Fig. 6a). We tes-
ted the efficiency of both CASFx constructs in activating endo-
genous SMN2-E7 inclusion in GM03813 fibroblast cells derived
from a type ll SMA patient. The homozygous deletion of exons 7
and 8 in the SMN1 gene allows us to quantify the splicing of
endogenous SMN2-E7 unambiguously. GM03813 cells were
nucleofected with an all-in-one plasmid carrying either CASFx-1
or RBFOX1N-dPspCas13b-C, a polycistronic three-gRNA array,
and a GFP marker. To isolate cells that have successfully taken up
the plasmids, we collected GFP positive cells via fluorescence-
activated cell sorting (FACS) 5 days after nucleofection. Subse-
quently, RT-PCR was applied to examine the extent of exon 7
inclusion of endogenous SMN2 transcripts. The expression level
of the exon7-included SMN2 isoform was promoted only in cells
transfected with both CASFx and SMN2-gRNAs (Fig. 6b, lane 3
and 5) and showed more than a 2-fold increase in inc/exc relative
ratio by CASFx-1 and a 2.75-fold increase by RBFOX1N-
dPspCas13b-C. These results not only demonstrate the applica-
tion of CASFx for modulating endogenous RNA splicing in
disease-relevant cell models, but also suggest that orthogonal
RNA-targeting CRISPR-Cas systems can be used to tether dif-
ferent splicing factors to regulate splicing processes, providing
options for engineering expanded libraries of artificial splicing
and RNA regulatory effectors.
Discussion
In this study, we reported the development of CASFx, artificial
splicing factors based on RNA-targeting CRISPR-Cas
systems30,31. CASFx with RBFOX1 or RBM38 fusions can induce
exon inclusion when targeted to bind at a downstream intron,
and induce exon exclusion when guided to bind within a target
exon. We also showed that simultaneous exon inclusion and
exclusion can be achieved by a pool of separate gRNAs or a
polycistronic pre-gRNA with multiple target-specific spacers. To
augment the controllability of the system, we engineered a
rapamycin-inducible CASFx (iCASFx), that allows small-
molecule control of alternative splicing. To demonstrate the
proof-of-principle application for studying alternative splicing in
diseases, we used CASFx to modulate clinically relevant SMN2-E7
inclusion in SMA patient fibroblasts.
CASFx offers many advantages compared with other strategies
for regulating alternative splicing. As we have demonstrated in
this study, CASFx provides higher specificity compared with
PUF-ESF and targeting can be easily programmed by changing
gRNAs without the need to engineer a new protein for each
unique target sequence, as is the case with PUF-ESF. Moreover,
unlike RNA-targeting with RCas926, dCasRx does not require an
additional PAMer oligo. In contrast to CRISPR/Cas9-mediated
genome editing strategies for perturbing splicing cis-regulatory
elements36–38, CASFx does not introduce permanent changes in
the genome and can be applied transiently and presumably
reversibly. Another main method to regulate alternative splicing
is to use ASO paring with specific regions of the pre-mRNA of
interest. Here too, CASFx offers advantages over the short-lived
effects of ASOs because CASFx can use various delivery vectors
for either transient or stable expression39. By incorporating
FKBP-FRB rapamycin-inducible domains, inducible CASFx
(iCASFx) allows an additional layer of splicing control via small
molecules. Taken together our results show that CASFx broadens
the CRISPR toolkit for studying and regulating alternative spli-
cing and represents a promising therapeutic solution for RNA
mis-splicing diseases.
Methods
Cloning. HEK293T cDNA was used as a source for PCR-amplification of coding
sequences of splicing factors or other RNA binding proteins. Alternatively, gBlocks
encoding human codon optimized versions of their coding sequences were ordered
from IDT to serve as the PCR template. The pXR002: EF1a-dCasRx-2A-EGFP 28
plasmid (Addgene #109050) served as PCR template for dCasRx coding sequence.
The pC0039-CMV-dPspCas13b-GS-ADAR2DD(E488Q) plasmid (Addgene
#103849) served as the template for dPspCas13b. The coding sequences of the
CRISPR Artificial Splicing Factors (CASFx) were then cloned into pmax expression
vector (Lonza) by a combination of fusion PCR, restriction-ligation cloning and
Sequence- and Ligation-Independent Cloning (SLIC)40. gRNA expression cloning
plasmids were generated by similar procedures using IDT oligonucleotides
encoding CasRx gRNA direct repeat and PCR reaction using a ccdbCam selection
cassette (Invitrogen) and a U6-containing plasmid as templates. Two BbsI
restriction sites flanking the ccdbCam selection cassette serves as the restriction
cloning sites for insertion of target-specific spacers. Target-specific spacer
sequences were then cloned into gRNA expression plasmids by annealed oligo-
nucleotide ligation. gRNA sequences are listed in supplementary Table 1. Plasmid
listing is included in the supplementary information. Plasmids and Genbank files
will be available on Addgene. Additional information will be available on http://
cheng.bio/casfx
Cell culture and transfection. HEK293T (ATCC), U2OS (ATCC), HeLa (ATCC)
and the SMA patient-derived fibroblasat line GM03813 (Coriell Institute) cells were
cultivated in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma) with 10% fetal
bovine serum (FBS)(Lonza), 4% Glutamax (Gibco), 1% Sodium Pyruvate (Gibco)
and penicillin-streptomycin (Gibco). Incubator conditions were 37 °C and 5%
CO2. For activation experiments, cells were seeded into 12-well plates at 100,000
cells per well the day before being transfected with 600 ng (the “quota”) of plasmid
DNA with 2.25 µL Attractene transfection reagent (Qiagen). Eighteen nanograms
of each reporter minigene plasmid was transfected. The remaining quota was then
divided equally among the effector and gRNA plasmids. In cases where there were
two or more gRNA plasmids, the quota allocated for gRNA plasmids is further
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subdivided equally. For ESF effectors, an equally split amount (194 ng) of all three
ESF plasmids were co-delivered as an ESF mix. For two-peptides effectors (i.e., the
FKBP-FRB systems), the effector plasmid quota was divided equally between the
plasmids encoding the individual peptides (146 ng). Media was changed 24 h after
transfection. Rapamycin (100 nM final concentration) was added during the media
change if applicable. Cells were harvested 48 h after transfection for RT-PCR
analysis.
SMA patient cell line nucleofection. Plasmid delivery by nucleofection was
performed using a Nucleofection X unit with the Nucleofection P2 kit (Lonza). For
each reaction, 1 × 106 cells were harvested and centrifuged at 100 × g for 3 min. The
cell pellet was then re-suspended carefully in P2 Solution and mixed together with
6 µg plasmid. EN-150 program was applied for nucleofection. Five days after
nucleofection, cells were trypsinized, suspended in media then sorted on The BD
FACSAria™ III sorter (BD Bioscience) to collect GFP positive cells.
RT-PCR. Cells were harvested for RNA extraction using RNeasy Plus Mini Kit
(Qiagen). Equal amounts of RNAs from one transfection experiment (either 700 or
1000 ng) were reverse-transcribed using a High Capacity RNA-to-cDNA Kit
(ThermoFisher). PCR was then performed using 2-µL cDNA using Phusion® High-
Fidelity DNA Polymerase (NEB) using minigene plasmid-specific primers for 25
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Fig. 5 Chemically inducible exon activation by iCASFx. a Schematic of the two-peptide CRISPR artificial splicing factors inducible by rapamycin. The RNA
binding module (FKBP- dCasRx or dCasRx-FKBP) and effector module (RBFOX1N-FRB-C) containing the splicing activator domains are expressed
separately as two peptides, fused to FKBP or FRB, respectively. FKBP and FRB can be induced to interact by rapamycin, bringing together the RNA binding
module and the splicing activator module, and when guided by gRNAs, assemble at the target to activate exon inclusion. b Upper panel shows inclusion/
exclusion (inc/exc) ratio fold-changes assayed by qRT-PCR on SMN2 minigene transcripts in cells co-transfected with the indicated constructs, and
cultured with (“+”) or without (“−”) rapamycin. Fold-changes are relative to GFP-transfected sample. Data are represented as mean ± SD (n= 3). Lower
panel shows a gel image of semi-quantitative splicing RT-PCR of SMN2 minigene transcripts in cells co-transfected with the indicated constructs, and
cultured with (“+”) or without (“−”) rapamycin. Uncropped gel images and qRT-PCR values are included in the Source Data file.
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cycles. The primer sequences are provided in Supplementary Table 2. PCR pro-
ducts were then analyzed on a 3% agarose gel.
Quantitative RT-PCR. Quantitative RT-PCR reactions were performed using a
LightCycler® 480 instrument (Roche) and the amplifications were done using the
SYBR Green PCR Master Mix (Roche). Biological and technical replicate reactions
were performed using 3 μL of diluted cDNA in a 10 μL reaction. All primer
sequences used are provided in Supplementary Table 2. The relative ratio of
inclusion/exclusion isoform was calculated using the ΔΔCt method and presented
as a fold change compared with WT cells.
RNA-seq and data analysis. Illumina Hiseq 2 × 150 bp sequencing was performed
by GENEWIZ. PolyA selection was applied for mRNA species in library preparation.
FASTQ raw sequence files were quality checked with FASTQC version 0.11.541. Low
quality reads and adapter sequences were trimmed by Trimmomatic version 0.3342.
Due to the length requirement of the downstream multivariate analysis of transcript
splicing (rMATS)43, reads were processed to match the same length of 135 bp based
on the QC report. Shorter reads were discarded and longer reads were trimmed to
remove the poor quality 3′ end. Mapping was performed by STAR aligner version
2.5.3 to the human genome (USCS RefSeq hg38 annotation)44. We then identify
transcriptome-wide splicing events by rMATS version 3.2.5 using UCSC RefSeq
hg38 GTF file as annotation. Each group was compared with the negative control
transfected with GFP plasmid alone (n= 2). The inclusion level difference (Δψ) of
each candidate exon skipping (SE) event was calculated using reads mapping to the
body of exons as well as to splice junctions. Considering that low coverage exons and
splicing junctions lead to low confidence inclusion levels, we filtered out the cases in
which average counts of two replicates for inclusion or skipping were <10. To
discover off-target SE event, we set the threshold parameters at | Δψ | ≥ 0.1 and false
discovery rate (FDR) ≤ 0.01. For the targeted SMN2 minigene, inclusion level dif-
ference (Δψ) was estimated based on minigene reads extracted from raw FASTQ files
containing 8 bp vector-specific sequences. Inclusion or exclusion isoforms of the
targeted minigene was then counted using these minigene reads based on their
junction site sequences.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that the data that support the findings of this study are included in
the published article and in the Supplementary Information, and are available from the
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Fig. 6 Exon activation in SMA patient cells by CASFx. a Schematic of the two all-in-one CASFx constructs (CASFx-1: RBFOX1N-dCasRx-C and RBFOX1N-
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corresponding author upon reasonable request. Data containing RNA-seq raw
sequencing read files were deposited onto sequencing read archive (SRA) with accession
number PRJNA624911 [https://www.ncbi.nlm.nih.gov/bioproject/PRJNA624911/].
Plasmids are available on the Addgene repository [https://www.addgene.org/browse/
article/28196786/]. Uncropped gel images presented in all figures, rMAT result tables,
qRT-PCR values are provided as a Source Data file. Source data are provided with
this paper.
Received: 11 December 2018; Accepted: 22 May 2020;
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